Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Essex Bio-Technology And 2 Other Undiscovered Gems In Asia

In This Article:

In the midst of global economic uncertainty and inflation fears, Asian markets are experiencing a period of cautious optimism, with investors navigating the complexities of trade policies and fluctuating consumer sentiment. As small-cap stocks in Asia present unique opportunities amid these conditions, identifying companies that demonstrate resilience and potential for growth becomes crucial for investors seeking to capitalize on undervalued assets.

Top 10 Undiscovered Gems With Strong Fundamentals In Asia

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Indofood Agri Resources

30.05%

2.36%

41.87%

★★★★★★

Shanghai Guangdian Electric Group

NA

-1.51%

-36.77%

★★★★★★

Korea Ratings

NA

0.74%

1.47%

★★★★★★

VICOM

NA

5.01%

2.30%

★★★★★★

Xuchang Yuandong Drive ShaftLtd

0.38%

-11.74%

-29.32%

★★★★★★

Yashima Denki

2.71%

-1.00%

18.12%

★★★★★★

Suzhou Highfine Biotech

NA

8.38%

9.44%

★★★★★★

Center International GroupLtd

27.06%

1.89%

-39.77%

★★★★★★

Taiyo KagakuLtd

0.73%

4.83%

-2.64%

★★★★★☆

Guangdong Transtek Medical Electronics

19.19%

-5.24%

-9.23%

★★★★★☆

Click here to see the full list of 2621 stocks from our Asian Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

Essex Bio-Technology

Simply Wall St Value Rating: ★★★★★★

Overview: Essex Bio-Technology Limited is an investment holding company engaged in the development, manufacturing, distribution, and sale of bio-pharmaceutical products across the People's Republic of China, Hong Kong, and international markets with a market capitalization of approximately HK$2.58 billion.

Operations: Essex Bio-Technology generates revenue primarily from its Surgical and Ophthalmology segments, contributing HK$879.90 million and HK$771.49 million, respectively. The company also earns from the provision of marketing services amounting to HK$18.42 million.

Essex Bio-Technology, a small player in the biotech scene, has seen its earnings grow 0.6% annually over five years, with recent net income reaching HK$307.22 million compared to HK$275.26 million last year. The company trades at 34.5% below its estimated fair value and boasts high-quality past earnings. Recent efforts include a phase 3 clinical study for an anti-VEGF ophthalmic injection product, HLX04-O, aiming to treat wet-AMD effectively against ranibizumab. Additionally, Essex announced a dividend increase to HKD 0.06 per share and plans amendments aligning with regulatory updates in Hong Kong's listing rules.